• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Bausch + Lomb files for initial public offering

Article

Bausch + Lomb has filed a registration statement with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock.

Rochester, NY-Bausch + Lomb has filed a registration statement with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. The number of shares to be offered and the price range for the proposed offering have not yet been determined.

For more articles in this issue of Ophthalmology Times eReport, click here.

Related Videos
Paul Badawi, co-founder and CEO of Sight Sciences, chats with Neda Shamie, MD, about what drives him
© 2024 MJH Life Sciences

All rights reserved.